MX2019009407A - Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes. - Google Patents
Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes.Info
- Publication number
- MX2019009407A MX2019009407A MX2019009407A MX2019009407A MX2019009407A MX 2019009407 A MX2019009407 A MX 2019009407A MX 2019009407 A MX2019009407 A MX 2019009407A MX 2019009407 A MX2019009407 A MX 2019009407A MX 2019009407 A MX2019009407 A MX 2019009407A
- Authority
- MX
- Mexico
- Prior art keywords
- vaccine compositions
- antigen
- immunostimulatory oligonucleotides
- novel vaccine
- component
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/008—Leishmania antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/27—Equine rhinopneumonitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invencion proporciona una composicion de vacuna que comprende un componente de antigeno y un componente de adyuvante, en la que el componente de adyuvante comprende un oligonucleotido inmunoestimulante de clase P y o bien una combinacion de una saponina y un esterol; o una fase oleosa que comprende un aceite y, opcionalmente, uno o mas emulsionantes, comprendiendo dicha fase oleosa el 2-20 % v / v de la composicion de vacuna, en la que dicho componente de antigeno es un antigeno del EHV o un antigeno de Leishmania.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361823189P | 2013-05-14 | 2013-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019009407A true MX2019009407A (es) | 2019-09-26 |
Family
ID=50897961
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015015758A MX367268B (es) | 2013-05-14 | 2014-05-12 | Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes. |
| MX2019009407A MX2019009407A (es) | 2013-05-14 | 2015-11-13 | Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015015758A MX367268B (es) | 2013-05-14 | 2014-05-12 | Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes. |
Country Status (20)
| Country | Link |
|---|---|
| EP (2) | EP3542819B1 (es) |
| JP (2) | JP6505084B2 (es) |
| CN (2) | CN108079290A (es) |
| AR (1) | AR096277A1 (es) |
| AU (2) | AU2014265649B2 (es) |
| BR (1) | BR112015028748A2 (es) |
| CA (2) | CA3027289A1 (es) |
| DK (1) | DK3542819T3 (es) |
| ES (2) | ES2742325T3 (es) |
| HK (1) | HK1219426A1 (es) |
| HR (1) | HRP20211452T1 (es) |
| HU (1) | HUE056040T2 (es) |
| LT (1) | LT3542819T (es) |
| MX (2) | MX367268B (es) |
| PL (1) | PL3542819T3 (es) |
| PT (2) | PT3542819T (es) |
| RU (1) | RU2627447C2 (es) |
| SI (1) | SI3542819T1 (es) |
| WO (1) | WO2014186291A1 (es) |
| ZA (1) | ZA201507774B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10456459B2 (en) * | 2015-07-20 | 2019-10-29 | Zoetis Services Llc | Liposomal adjuvant compositions |
| JP6975132B2 (ja) * | 2015-07-20 | 2021-12-01 | ゾエティス・サービシーズ・エルエルシー | リポソームアジュバント組成物 |
| BE1023538B1 (fr) * | 2016-04-22 | 2017-04-26 | Sil'innov Scrl | Silices mésoporeuses et leur procédé de synthèse |
| TW202206098A (zh) * | 2020-08-11 | 2022-02-16 | 美商碩騰服務公司 | 抗冠狀病毒疫苗 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7904021A (nl) * | 1979-05-22 | 1980-04-29 | Gist Brocades Nv | Gecombineerd vaccin en werkwijze voor het bereiden van dit gecombineerd vaccin tegen door adeno achtige virussen veroorzaakte eiproduktiedalingen en door reo virus veroorzaakte ziekteverschijnselen. |
| US6803041B2 (en) * | 2001-03-20 | 2004-10-12 | Boehringer Ingelheim Vetmedica, Inc. | Equine herpesvirus vaccine |
| CA2452545C (en) * | 2001-07-27 | 2015-06-09 | Wyeth | West nile vaccine comprising live attenuated, inactivated or killed whole or subunit west nile virus |
| JP2005532067A (ja) * | 2002-07-03 | 2005-10-27 | コーリー ファーマシューティカル グループ，インコーポレイテッド | 刺激性免疫応答用の核酸組成物 |
| GB0409940D0 (en) * | 2004-05-04 | 2004-06-09 | Glaxosmithkline Biolog Sa | Vaccine |
| US20070166800A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant |
| MX2009003398A (es) * | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada. |
| MX2009003325A (es) * | 2006-10-12 | 2009-04-09 | Glaxosmithkline Biolog Sa | Vacuna que comprende un adyuvante de emulsion de aceite en agua. |
| MX347471B (es) * | 2010-05-28 | 2017-04-24 | Zoetis Belgium S A | Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas. |
| EP2637687B1 (en) * | 2010-11-08 | 2021-01-06 | Infectious Disease Research Institute | Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis |
-
2014
- 2014-05-12 DK DK19173426.8T patent/DK3542819T3/da active
- 2014-05-12 LT LTEP19173426.8T patent/LT3542819T/lt unknown
- 2014-05-12 CA CA3027289A patent/CA3027289A1/en not_active Abandoned
- 2014-05-12 EP EP19173426.8A patent/EP3542819B1/en active Active
- 2014-05-12 PT PT191734268T patent/PT3542819T/pt unknown
- 2014-05-12 RU RU2015146752A patent/RU2627447C2/ru active
- 2014-05-12 CN CN201810130911.4A patent/CN108079290A/zh active Pending
- 2014-05-12 AU AU2014265649A patent/AU2014265649B2/en active Active
- 2014-05-12 JP JP2016514012A patent/JP6505084B2/ja active Active
- 2014-05-12 MX MX2015015758A patent/MX367268B/es active IP Right Grant
- 2014-05-12 CA CA2911938A patent/CA2911938C/en active Active
- 2014-05-12 ES ES14729191T patent/ES2742325T3/es active Active
- 2014-05-12 BR BR112015028748A patent/BR112015028748A2/pt not_active Application Discontinuation
- 2014-05-12 ES ES19173426T patent/ES2894138T3/es active Active
- 2014-05-12 WO PCT/US2014/037705 patent/WO2014186291A1/en active Application Filing
- 2014-05-12 SI SI201431889T patent/SI3542819T1/sl unknown
- 2014-05-12 PL PL19173426T patent/PL3542819T3/pl unknown
- 2014-05-12 CN CN201480027344.XA patent/CN105263518B/zh active Active
- 2014-05-12 PT PT14729191T patent/PT2996719T/pt unknown
- 2014-05-12 EP EP14729191.8A patent/EP2996719B1/en active Active
- 2014-05-12 HR HRP20211452TT patent/HRP20211452T1/hr unknown
- 2014-05-12 HU HUE19173426A patent/HUE056040T2/hu unknown
- 2014-05-13 AR ARP140101927A patent/AR096277A1/es unknown
-
2015
- 2015-10-16 ZA ZA2015/07774A patent/ZA201507774B/en unknown
- 2015-11-13 MX MX2019009407A patent/MX2019009407A/es unknown
-
2016
- 2016-06-28 HK HK16107491.1A patent/HK1219426A1/zh unknown
-
2017
- 2017-09-25 AU AU2017232231A patent/AU2017232231A1/en not_active Abandoned
-
2019
- 2019-01-31 JP JP2019015717A patent/JP2019108328A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201903620B (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof | |
| HUS2200035I1 (hu) | Konjugált burokszaccharid antigéneket tartalmazó immunogén készítmények és alkalmazásaik | |
| MX2016003658A (es) | Coadyuvantes basados en aceite. | |
| EP3662927A3 (en) | Vaccine composition | |
| MX2023012979A (es) | Procedimiento para fabricar un adyuvante. | |
| CR20160502A (es) | Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso | |
| EP3669891A4 (en) | VACCINE ADJUVANS WITH LIPOPEPTIDE-INSERTED LIPOSOME AS THE ACTIVE SUBSTANCE AND USE OF IT | |
| MX2019009407A (es) | Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes. | |
| IL276661B1 (en) | Immunogenic preparation containing staphylococcal antigens | |
| PH12019501569A1 (en) | Universal influenza vaccine compositions | |
| ZA202101173B (en) | Composition containing influenza vaccine | |
| IN2014CN03454A (es) | ||
| SG11202009147UA (en) | Vaccine compositions | |
| EP3730620A4 (en) | CROSS-IMMUNIZATION ANTIGENIC VACCINE AND PROCESS FOR PREPARATION | |
| MX2015015428A (es) | Eliminacion de riesgo de narcolepsia en vacunas contra influenza. | |
| RS62793B1 (sr) | Heterobasidion annosum ekstrakt protiv kancera, kompozicije i njihova primena | |
| EP3710051A4 (en) | Vaccine compositions | |
| PH12018500146A1 (en) | Liposomal adjuvant compositions | |
| EP3585885A4 (en) | INFLUENZA IMMUNOGENIC COMPOSITIONS | |
| GB201809541D0 (en) | Vaccine compositions | |
| GB201805393D0 (en) | Vaccine compositions | |
| IN2014DE00010A (es) |